Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting

被引:47
作者
Halperin, Abigail C. [1 ,2 ]
McAfee, Timothy A. [2 ]
Jack, Lisa M. [3 ]
Catz, Sheryl L. [4 ]
McClure, Jennifer B. [4 ]
Deprey, T. Mona [2 ]
Richards, Julie [4 ]
Zbikowski, Susan M. [2 ]
Swan, Gary E. [3 ]
机构
[1] Univ Washington, Seattle, WA 98105 USA
[2] Free & Clear Inc, Seattle, WA 98104 USA
[3] SRI Int, Menlo Pk, CA 94025 USA
[4] Ctr Hlth Studies, Grp Hlth, Seattle, WA 98101 USA
关键词
Varenicline; Smoking cessation; Tobacco dependence treatment; RECEPTOR PARTIAL AGONIST; SUSTAINED-RELEASE BUPROPION; RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; GENDER-DIFFERENCES; PLACEBO; EFFICACY; SAFETY;
D O I
10.1016/j.jsat.2008.09.001
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
This article examines reported symptoms, nonsmoking rates, and medication use among 1,018 smokers using varenicline in a randomized trial comparing three forms of behavioral support for smoking cessation (phone, Web, or phone + Web). One month after beginning varenicline, 168 people (17%) had discontinued the medication. Most (53%) quit due to side effects and other symptoms. The most common side effect among all users was nausea (reported by 57% of users). At 1 month post medication initiation, those not taking varenicline were more likely to report smoking than those who continued the medication (57% vs. 16%. p<.001). Women reported more symptoms but did not discontinue medication at higher rates. Participants who received any telephone counseling (n = 681) were less likely to discontinue their medication than those with Web support only (15% vs. 2%, p<.01). Counseling may improve tolerance of this medication and reduce the rate of discontinuation due to side effects. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 14 条
[1]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[2]   Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial [J].
Gonzales, David ;
Rennard, Stephen I. ;
Nides, Mitchell ;
Oncken, Cheryl ;
Azoulay, Salomon ;
Billing, Clare B. ;
Watsky, Eric J. ;
Gong, Jason ;
Williams, Kathryn E. ;
Reeves, Karen R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01) :47-55
[3]   Effects of abstinence from tobacco: Valid symptoms and time course [J].
Hughes, John R. .
NICOTINE & TOBACCO RESEARCH, 2007, 9 (03) :315-327
[4]   Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation -: A randomized controlled trial [J].
Jorenby, Douglas E. ;
Hays, J. Taylor ;
Rigotti, Nancy A. ;
Azoulay, Salomon ;
Watsky, Eric J. ;
Williams, Kathryn E. ;
Billing, Clare B. ;
Gong, Jason ;
Reeves, Karen R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01) :56-63
[5]   PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2) [J].
Leabman, MK ;
Huang, CC ;
Stryke, D ;
Johns, SJ ;
Kawamoto, M ;
Ferrin, TE ;
Deyoung, J ;
Taylor, TR ;
De La Cruz, M ;
Herskowitz, I ;
Giacomini, KM .
PHARMACOLOGICAL REVIEWS, 2003, 55 (03) :399-399
[6]   Gender differences in acute tobacco withdrawal: Effects on subjective, cognitive, and physiological measures [J].
Leventhal, Adam M. ;
Waters, Andrew J. ;
Boyd, Susan ;
Moolchan, Eric T. ;
Lerman, Caryn ;
Pickworth, Wallace B. .
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2007, 15 (01) :21-36
[7]   Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist -: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up [J].
Nides, Mitchell ;
Oncken, Cheryl ;
Gonzales, David ;
Rennard, Stephen ;
Watsky, Eric J. ;
Anziano, Rich ;
Reeves, Karen R. .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (15) :1561-1568
[8]   Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation [J].
Oncken, Cheryl ;
Gonzales, David ;
Nides, Mitchell ;
Rennard, Stephen ;
Watsky, Eric ;
Billing, Clare B. ;
Anziano, Richard ;
Reeves, Karen .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (15) :1571-1577
[9]  
*PFIZ LABS, 2006, CHANT VAR TABL
[10]  
SAS Institute Inc, 2002, SAS 9 1 HELP DOC